CryoPort, Inc. (NASDAQ:CYRX) Given Average Recommendation of "Buy" by Analysts

Key Points

• CryoPort, Inc. has received an average analyst rating of "Buy" from ten brokerages, with a **1-year target price** of $12.56.
• Recent transactions include insider sales, with Director Robert J. Hariri selling **25,000 shares** at an average price of $9.71, reducing his overall stake by **32.78%**.
• Large investors have significantly increased their stakes in CryoPort, with **Nisa Investment Advisors increasing** its investment by nearly **300%** in the second quarter alone.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) has earned an average rating of "Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $12.5556.

A number of analysts have recently issued reports on CYRX shares. BTIG Research lifted their price target on CryoPort from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Stephens started coverage on CryoPort in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 target price for the company. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price for the company in a research report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Wednesday, August 6th. Finally, Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th.

Insider Buying and Selling

In other CryoPort news, Director Robert J. Hariri sold 25,000 shares of CryoPort stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $9.71, for a total value of $242,750.00. Following the transaction, the director directly owned 51,275 shares of the company's stock, valued at $497,880.25. The trade was a 32.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction that occurred on Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the transaction, the director directly owned 92,328 shares in the company, valued at $668,454.72. This trade represents a 30.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 80,028 shares of company stock worth $661,252 in the last quarter. 10.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CryoPort

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its stake in CryoPort by 299.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after purchasing an additional 2,729 shares during the period. Tower Research Capital LLC TRC increased its stake in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares during the period. SBI Securities Co. Ltd. increased its stake in CryoPort by 548,750.0% in the 1st quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after purchasing an additional 10,975 shares during the period. CWM LLC increased its stake in CryoPort by 1,437.0% in the 1st quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares during the period. Finally, ProShare Advisors LLC purchased a new position in CryoPort in the 2nd quarter worth approximately $75,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Stock Performance

Shares of CYRX opened at $9.20 on Monday. The company has a market cap of $460.64 million, a PE ratio of 6.92 and a beta of 1.62. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average price of $8.64 and a 200-day moving average price of $7.16. CryoPort has a 12-month low of $4.58 and a 12-month high of $10.46.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that CryoPort will post -0.99 earnings per share for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.